Approximately 30% of patients with undifferentiated arthritis develop rheumatoid arthritis – a chronic, inflammatory disease causing deformity of the affected joints. Depending on geographical location, rheumatoid arthritis affects between 0.3 and 2% of the world’s population. Correct diagnosis and monitoring of patients is extremely important.
RheumaKit provided by DNAlytics (Louvain-la-Neuve) is an innovative solution for the diagnosis of undifferentiated arthritis. The system combines the sample collection and transportation kit, laboratory processing, and a web-based application with an embedded predictive model.
The Massachusets Institute of Technology (MIT), a prestigious engineering school renowned for its innovative spirit, recently recognized DNAlytics’ work. Thibault Helleputte, CEO of the company, was nominated for the ‘MIT innovators under 35’ award.
DNAlytics offers tailored on-demand consultancy services in data mining for pharmaceutical, research laboratories, and biotechnology and IVD companies. RheumaKit is their first IVD CE-labeled diagnostic product.
Menu
